

Financial Tear Sheet




Corporate Profile

Who is Organovo?

- We participate in attractive and growing markets with critical unmet needs
- We benefit from favorable competitive dynamics and a first mover advantage
- We're a technology leader with a strong IP portfolio
- We're leveraging our technology platform to build a robust product and service platform across the preclinical safety, efficacy and disease modeling and therapeutic tissues markets

Primary IR Contact

Steve E. Kunszabo
 VP, Investor Relations &
 Corporate
 Communications
Phone: 858-224-1092
Email:
 skunszabo@organovo.com

 2016 Annual Report
  Investor Fact Sheet
  Investor Presentation

Stock Information

ONVO (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$2.74
Change (%)	▼ 0.02 (0.72%)
Volume	572,416
52 Week Low	\$2.48
Market Cap	\$288,654,134
Rolling EPS	-0.39
PE Ratio	0
Shares Outstanding	104,584,831
Data as of 06/26/17 4:00 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releases & Upcoming Events

06/07/17

Organovo Announces Fiscal Fourth-Quarter and Full-Year 2017 Results; Company Issues Full-Year Fiscal 2018 Outlook

06/05/17

Organovo to Present at Jefferies Healthcare Conference

05/18/17

Organovo Presents New Preclinical Data on 3D Bioprinted Human Liver Tissues at World Advanced Therapies and Regenerative Medicine Congress

There are currently no events scheduled.

SEC Filings

Filing Date	Form
06/07/17	10-K
06/07/17	8-K
05/17/17	4
05/17/17	4

Corporate Governance

Taylor J. Crouch	President & Chief Executive Officer
Sharon Collins Presnell, Ph.D.	Chief Scientific Officer, Organovo & President, Samsara
Eric Michael David, M.D., J.D.	Chief Strategy Officer and Executive Vice President of Preclinical Development
Jennifer Kinsbruner Bush, J.D.	General Counsel, Corporate Secretary and Compliance Officer
Susan Daugherty	Vice President, Human Resources
Paul Gallant	General Manager